NCNA VS NEPH Stock Comparison

Performance

NCNA
10/100

NCNA returned -59.09% in the last 12 months. Based on SPY's performance of 11.53%, its performance is below average giving it a score of 10 of 100.

NEPH
100/100

NEPH returned 93.36% in the last 12 months. Based on SPY's performance of 13.09%, its performance is above average giving it a score of 100 of 100.

Analyst Price Targets

NCNA
94/100

4 analysts offer 12-month price targets for NCNA. Together, they have an average target of 0, the most optimistic target put NCNA at 0 within 12-months and the most pessimistic has NCNA at 0.

NEPH

"Analyst Price Targets" not found for NEPH

Sentiment

NCNA
65/100

NCNA had a bullish sentiment score of 65.09% across Twitter and StockTwits over the last 12 months. It had an average of 2.33 posts, 1.33 comments, and 2.58 likes per day.

NEPH

"Sentiment" not found for NEPH

Technicals

NCNA
11/100

NCNA receives a 10 of 100 based on 14 indicators. 1 are bullish, 12 are bearish.

NEPH
89/100

NEPH receives a 89 of 100 based on 14 indicators. 12 are bullish, 1 are bearish.

Earnings

NCNA
10/100

NCNA has missed earnings 7 times in the last 20 quarters.

NEPH
10/100

NEPH has missed earnings 6 times in the last 20 quarters.

Profit

NCNA
10/100

Out of the last 20 quarters, NCNA has had 0 profitable quarters and has increased their profits year over year on 0 of them.

NEPH
10/100

Out of the last 20 quarters, NEPH has had 0 profitable quarters and has increased their profits year over year on 0 of them.

Volatility

NCNA
54/100

NCNA has had a higher than average amount of volatility over the last 12 months giving it a score of 53 of 100.

NEPH
53/100

NEPH has had a higher than average amount of volatility over the last 12 months giving it a score of 52 of 100.

All score calculations are broken down here to help you make more informed investing decisions

NuCana plc American Depositary Share Summary

Nasdaq / NCNA

Healthcare

Biotechnology

NuCana plc, a clinical-stage biopharmaceutical company, engages in the development of products for the treatment of cancer. The company develops its products based on its proprietary ProTide technology. Its lead product candidate includes Acelarin, which is in Phase I clinical trial for patients with advanced solid tumors; Phase Ib for patients with recurrent ovarian cancer; Phase Ib clinical trials for the treatment of patients with biliary tract cancer; Phase II clinical trial for the treatment of patients with platinum-resistant ovarian cancer; and Phase III clinical trial for the treatment of patients with pancreatic cancer. The company is also developing NUC-3373, a ProTide transformation of the active anti-cancer metabolite of 5-fluorouracil, which is in Phase I clinical trial for the treatment of patients with advanced solid tumors and in a Phase 1b/2 clinical trial for patients with advanced colorectal cancer; and NUC-7738, a nucleoside analog that is in Phase 1/2 clinical trial for the treatment of patients with advanced solid tumors and hematological tumors. It has a research, collaboration, and license agreement with Cardiff University and University College Cardiff Consultants Ltd. for the design, synthesis, characterization, and evaluation of ProTides; and an assignment, license, and collaboration agreement with Cardiff ProTides Ltd. The company was formerly known as NuCana BioMed Limited and changed its name to NuCana plc in August 2017. NuCana plc was incorporated in 1997 and is headquartered in Edinburgh, the United Kingdom.

Nephros Inc. Summary

Nasdaq / NEPH

Healthcare

Medical - Instruments & Supplies

Nephros, Inc. develops and sells high performance water solutions to the medical and commercial markets in the United States. The company operates in three segments: Water Filtration, Pathogen Detection, and Renal Products. It offers ultrafiltration products that are used in dialysis centers for the removal of biological contaminants from water and bicarbonate concentrate; and in hospitals for the prevention of infection from waterborne pathogens, such as legionella and pseudomonas, as well as in military and outdoor recreation, commercial, and other healthcare facilities. The company also develops and sells real-time water testing systems to provide actionable data on waterborne pathogens; and medical device products for patients with renal disease, including a 2nd generation hemodiafiltration system for the treatment of patients with end stage renal disease. In addition, it offers water filters that improve the taste and odor of water, as well as reduce biofilm, bacteria, and scale build-up in downstream equipment under the Nephros and AETHER brands for the food service, hospitality, convenience store, and health care markets. The company was incorporated in 1997 and is headquartered in South Orange, New Jersey.

Power up your portfolio